Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director · President and CEO | December 17, 2025 | December 19, 2025 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | President and CEO · 10% owner | February 07, 2019 | February 11, 2019 |
| GRI Bio, Inc.VLON · Entity 8336 | Director | June 09, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2035-12-17 | Direct | 175,000 |
Reported balance
After 2025-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-17 · Grant · Acquired 175,000 · Balance 175,000 F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
Arcturus Therapeutics Ltd.
Report date February 07, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2029-02-06 | Direct | 60,000 |
Reported balance
After 2019-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-07 · Grant · Acquired 60,000 · Balance 60,000 F1: The grant of options to the Reporting Person is subject to shareholder approval under the Companies Law 5759-1999 of the State of Israel; options vest over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of options to the Reporting Person is subject to shareholder approval under the Companies Law 5759-1999 of the State of Israel; options vest over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter.
GRI Bio, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2032-06-09 | Direct | 7,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 7,500 · Balance 7,500 F1: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2025 Filed Dec 19, 2025 17:21 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001193805-25-001765 · e665059_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-12-17 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 16:06 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 196,000 | $0.00 Strike: $16.24 | $0.00 |
DisclosureSEC source: 0001193805-24-001492 · e664085_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 Underlying: Common Stock · 196,000 shares Expires 2034-12-16 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001193805-23-001626 · e619133_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-15 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 16:07 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $16.92 | $0.00 |
DisclosureSEC source: 0001193805-22-001715 · e618108_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-12-09 F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 16:07 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 5,000 | $16.51 | $82,550.00 |
DisclosureSEC source: 0001193805-22-001614 · e618061_4-payne.xml · nonDerivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480,097 F1 · price: Represents the purchase price paid by the Reporting Person for the shares of common stock, $0.001 par value per share, of the Registrant, in an open market transaction. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 16:16 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $34.57 | $0.00 |
DisclosureSEC source: 0001193805-22-001001 · e621772_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-12-10 F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 13:32 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001824293-22-000055 · wf-form4_165488230708266.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| May 26, 2021 Filed May 27, 2021 20:37 UTC | GRI Bio, Inc. VLON · Entity 8336 | PurchaseCommon Stock | 6,800 | $4.50 | $30,600.00 |
DisclosureSEC source: 0001104659-21-073495 · tm2117820-1_4.xml · nonDerivative · entry 2 Payne Joseph E · CIK 0001727315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:37 UTC | GRI Bio, Inc. VLON · Entity 8336 | PurchaseCommon Stock | 10,700 | $3.85 | $41,195.00 |
DisclosureSEC source: 0001104659-21-073495 · tm2117820-1_4.xml · nonDerivative · entry 1 Payne Joseph E · CIK 0001727315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:09 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 14,286 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068839 · tm2116776-7_4.xml · derivative · entry 2 Payne Joseph E · CIK 0001727315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,286 Underlying: Common Stock · 14,286 shares Expires 2031-05-14 F2 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021. Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:09 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068839 · tm2116776-7_4.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 19:40 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $99.29 | $0.00 |
DisclosureSEC source: 0001193805-20-001609 · e620163_4-payne.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 21:59 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 1,000 | $31.69 | $31,690.00 |
DisclosureSEC source: 0000899243-20-016050 · doc4.xml · nonDerivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475,097 F1 · balance_after: 183,137 shares are subject to repurchase by the Company. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 20:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.12 | $0.00 |
DisclosureSEC source: 0000899243-20-005379 · doc4.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 17:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 5,000 | $11.22 | $56,100.00 |
DisclosureSEC source: 0000899243-19-022619 · doc4.xml · nonDerivative · entry 1 Payne Joseph E · CIK 0001727315 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,474,097 F1 · balance_after: Includes 366,274 ordinary shares subject to repurchase pursuant to a Common Stock Purchase Agreement, dated March 4, 2013, as amended on September 27, 2017, by and between the Reporting Person and the Issuer. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:21 UTC | Arcturus Therapeutics Ltd. ARCT · Entity 160417 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $4.99 Strike: $4.99 | $299,400.00 |
DisclosureSEC source: 0001566049-19-000006 · edgardoc.xml · derivative · entry 1 Payne Joseph E · CIK 0001727315 · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The grant of options to the Reporting Person is subject to shareholder approval under the Companies Law 5759-1999 of the State of Israel; options vest over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.